Camptothecin induces the transit of FasL trimers to the cell surface in apoptotic HEp-2 cells

Cellular and Molecular Biology Letters

Volumn 11, Issue 3, 2006, Pages 299-311

  Meza Lamas, Esteban ^a   Bollain Y Goytia, Juan José ^a   Ramírez Sandoval, Roxana ^a   Sánchez Rodríguez, Sergio H ^a   López Robles, Erendira ^a   Avalos Díaz, Esperanza ^a   Herrera Esparza, Rafael ^a  

^a UNIVERSIDAD AUTÓNOMA DE ZACATECAS   (Mexico)

Author keywords

Apoptosis; Camptothecin; FasL; Oligomerization; TUNEL

Indexed keywords

CAMPTOTHECIN; CASPASE; FAS LIGAND; MEMBRANE PROTEIN; MONOMER; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL FRACTIONATION; CELL SURFACE; CONTROLLED STUDY; DRUG MECHANISM; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE;

EID: 33749353185     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.2478/s11658-006-0025-3     Document Type: Article

References (26)

1. Siegel, R.M., Frederiksen, J.K., Zacharias, D.A., Chan, F.K., Johnson, M., Lynch, D., Tsien, R.Y. and Lenardo, M.J. Fas pre association required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288 (2000) 2354-2357.
2. Nagata, S. and Goldstein, P. The Fas death factor. Science 267 (1995) 1449-1456.
3. Muller, M., Strand, S., Hug, H., Heinemann, E-M., Walczak, H., Hoffman, W.J., Stremmel, W., Krammer, P.H. and Galle, P.R. Drug-induced apoptosis in hepatoma cells is mediated by CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99 (1997) 403-413.
4. Fulda, S., Sieverts, H., Friesen, C., Herr, I. and Debatin, K.M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer. Res. 57 (1997) 3823-3829.
5. Fulda, S., Friesen, C., Los, M., Scaffidi, C., Mier, W., Benedict, M., Nuñez, G., Krammer, P.H., Peter, M.E. and Debatin, K.M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer. Res. 57 (1997) 4956-4965.
6. Chatterjee, D., Schmitz, I., Krueger, A., Yeung, K., Kirchhoff, S., Krammer, P.H., Peter, M.E., Wyche, J.H. and Pantazis, P. Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and downregulation of c-FLIP. Cancer. Res. 61 (2001) 7148-7154.
7. Wesselborg, S., Engels, I.H., Rossmann, E., Los, M. and Schulze-Osthoff, K. Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction. Blood 93 (1999) 3053-3063.
8. Giordano, C., Stassi, G., DeMaría, R., Todaro, M., Richiusa, P., Papoff, G., Ruberti, G., Bagnasco, M., Testi, R. and Galluzzo, A. Potential involvement of Fas and its ligand in pathogenesis of Hashimoto's thyroiditis. Science 275 (1997) 960-963.
9. Ragnarsson, G.B., Mikaelsdottir, E.K., Vidarsson, H., Jonasson, J.G, Olafsdottir, K., Kristjansdottir, K., Kjartansson, J., Ogmundsdottir, H.M. and Rafnar, T. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br. J. Cancer 83 (2000) 1715-1721.
10. Hamann, K.J., Dorscheid, D.R., Ko, F.D., Conforti, A.E., Sperling, A.I., Rabe, K.F. and White, S.R. Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium. Am. J. Respir. Cell. Mol. Biol. 19 (1998) 537-542.
11. Bennett M.W., O'Connell J., O'Sullivan, G.C., Roche, D., Brady, C., Collins, J.K. and Shanahan, F. Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover. Dis. Esophagus 12 (1999) 90-98.
12. Gilbert, S., Loranger, A., Daigle, N. and Marceau, N. Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J. Cell. Biol. 154 (2001) 763-773.
13. Tan, K.H. and Hunziker, W. Compartmentalization of Fas and Fas ligand may prevent auto-or paracrine apoptosis in epithelial cells. Exp. Cell. Res. 284 (2003) 281-288.
14. Nisihara, T., Ushio, Y., Higuchi, H., Kayagaki, N., Yamaguchi, N., Soejima, K., Matsuo, S., Maeda, H., Eda, Y., Okumura, K. and Yagita, H. Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: Structural insights into Fas/Fas ligand interaction. J. Immunol. 167 (2001) 3266-3275.
15. Rothenberg, M.L. Topoisomerase I inhibitors-Review and update. Ann. Oncol. 8 (1997) 837-855.
16. Deng, G.R. and Wu, R. Terminal transferase: use in the tailing of DNA and for in vitro mutagenesis. Meth. Enzymol. 100 (1983) 96-116.
17. Laemmli, U.K. and Favre, M. Maturation of the head of bacteriophage T4 I DNA packaging events. J. Mol. Biol. 80 (1973) 575-599.
18. Towbin, H.T., Staehlin, T. and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocelulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. USA. 76 (1977) 4350-4354.
19. Vaishnaw, A.K., Orlinick, J.R., Chu, J.L., Krammer, P.H., Chao, M.V and Elkon, K.B. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J. Clin. Invest. 103 (1999) 355-363.
20. Iguchi, K., Hirano, K. and Ishida, R. Activation of caspase-3, proteolytic cleavage of DFF and No oligonucleosomal DNA fragmentation in apoptotic Molt-4 cells. J. Biochem. 131 (2002) 469-475.
21. Wang, A.M. and Mark, D.F. Quantitative PCR. In: PCR Protocols. A guide to methods and applications. Innis, M.A., Gelfand, D.H., Snisky, J.J., Withe, T.J., eds, Academic Press. San Diego, USA: 1990 pp 70-75
22. Cremesti, A., Paris, F., Grassme, H., Holler, N., Tschopp, J., Fuks, Z., Gulbins, E. and Kolesnick, R. Ceramide enables fas to cap and kill. J. Biol. Chem. 276 (2001) 23954-23961.
23. Schneider, P., Holler, N., Bodmer, J.L., Hahne, M., Frei, K., Fontana, A. and Tschopp, J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187 (1998) 1205-12013.
24. Schneider, P., Bodmer, J.L., Holler, N., Mattmann, C., Scuderi, P., Terskikh, A., Peitsch, M. C. and Tschopp, J. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J. Biol. Chem. 272 (1997) 18827-18833.
25. Henkler, F., Behrle, E., Dennehy, K. M., Wicovsky, A., Peters, N., Warnke, C., Pfizenmaier, K. and Wajant, H. The extracellular domains of FasL and Fas are sufficient for the formation of supramolecular FasL-Fas clusters of high stability. J. Cell. Biol. 168 (2005) 1087-10898.
26. Orlinick, J.R., Elkon, K.B. and Chao, M.V. Separate domains of the human fas ligand dictate self-association and receptor binding. J. Biol. Chem. 272 (1997) 32221-32229.